Skip to main content
. Author manuscript; available in PMC: 2024 Oct 13.
Published in final edited form as: Vaccine. 2023 Sep 14;41(43):6461–6469. doi: 10.1016/j.vaccine.2023.08.071

Table 1.

Key vaccine parameters

Parameter Description Value
Prevalence Prevalence of HIV-1 at baseline 10%
Coverage Percentage of total population who are vaccinated 10%, 30%, 50%, 70%, or 90%
Vaccine decrement Difference between genotypic and temporary phenotypic SPVL due to vaccine 0.5, 1.0, 1.5, 2.0 log10 copies/ml
Efficacy duration Length of time before vaccinated agents lose vaccine effect 3 years
Vaccination campaign duration Length of time for which vaccination coverage is maintained 30 years
Heritability Proportion of new infectee’s SPVL attributable to the SPVL of the donor, vs random chance 36%